| Schedule of Earning Per Share |
Diluted EPS excludes all dilutive potential
shares if their effect is anti-dilutive.
| |
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
| |
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
| Net income (loss) computation of basic and diluted net loss per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income (loss) |
|
$ |
120,835 |
|
|
$ |
(2,689,342 |
) |
|
$ |
(6,152,982 |
) |
|
$ |
(2,181,707 |
) |
| Less: Redemption of Series D Preferred Stock deemed dividend |
|
|
- |
|
|
|
- |
|
|
|
(1,295,294 |
) |
|
|
- |
|
| Less: Common stock deemed dividend (inducement cost) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(2,137,190 |
) |
| Net income (loss) attributable to common stockholders |
|
$ |
120,835 |
|
|
$ |
(2,689,342 |
) |
|
$ |
(7,448,276 |
) |
|
$ |
(4,318,897 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic and diluted net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic net income (loss) per common share |
|
$ |
0.00 |
|
|
$ |
(0.87 |
) |
|
$ |
(0.32 |
) |
|
$ |
(2.27 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic weighted average common shares outstanding |
|
|
38,414,631 |
|
|
|
3,084,456 |
|
|
|
23,154,481 |
|
|
|
1,906,179 |
|
| Diluted net income (loss) per common share |
|
$ |
0.00 |
|
|
$ |
(0.87 |
) |
|
$ |
(0.32 |
) |
|
$ |
(2.27 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diluted weighted average common shares outstanding |
|
|
38,414,631 |
|
|
|
3,084,456 |
|
|
|
23,154,481 |
|
|
|
1,906,179 |
|
|
| Schedule of Potential Dilutive Securities |
Potentially dilutive securities that are not
included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows as of September
30, (in common equivalent shares):
| |
|
2020 |
|
|
2019 |
|
| Warrants |
|
|
21,925,102 |
|
|
|
1,183,877 |
|
| Series A & B Notes |
|
|
213,105 |
|
|
|
- |
|
| Options and restricted stock units |
|
|
197,193 |
|
|
|
106,538 |
|
| Total anti-dilutive weighted average shares |
|
|
22,335,400 |
|
|
|
1,290,415 |
|
|